Business Context and Reporting Period
Company: Synthetic Blood International, Inc. (Note: Metadata referenced "Tenax Therapeutics," but the filing text identifies the registrant as Synthetic Blood International, Inc.)
Reporting Period: Quarterly period ended January 31, 1997 (Three and Nine Months).
Status: Development Stage Enterprise. The company is in the pre-clinical trial stage of its products, which require further development and FDA approval before marketing. The filing includes a "Going Concern" warning, stating that substantial doubt exists regarding the company's ability to continue operations without additional financing.
Key Financial Metrics
| Metric | Three Months Ended Jan 31, 1997 | Nine Months Ended Jan 31, 1997 | Balance Sheet (Jan 31, 1997) |
|---|---|---|---|
| Revenue | $0 | $0 | N/A |
| Net Loss | $(324,751) | $(1,351,554) | Accumulated Deficit: $(7,728,310) |
| Operating Expenses | $322,418 | $1,348,159 | N/A |
| Cash and Equivalents | N/A | N/A | $7,560 |
| Working Capital | N/A | N/A | Deficit of $(557,518) |
| Total Liabilities | N/A | N/A | $595,041 |
| Stockholders' Equity | N/A | N/A | $(289,851) |
| Shares Outstanding | 38,485,094 | 38,485,094 | 38,485,094 |
Cash Flow Summary (Nine Months Ended Jan 31, 1997):
- Net cash used in operating activities: $(1,094,561)
- Net cash used in investing activities: $(19,060)
- Net cash provided by financing activities: $1,044,869 (primarily from stock sales and convertible debentures).
Material Changes vs. Prior Period
- Expense Reduction: Research and Development (R&D) expenses decreased significantly to $156,628 for the three months ended Jan 31, 1997, compared to $194,322 in the prior year. General and Administrative (G&A) expenses also declined to $165,790 from $275,221.
- Net Loss Improvement: The net loss for the three-month period narrowed to $(324,751) from $(470,694) in the prior year, attributed to reduced research staff and outside laboratory testing.
- Liquidity Deterioration: Cash balances dropped from $76,312 at April 30, 1996, to $7,560 at January 31, 1997. Total current liabilities decreased from $974,969 to $590,099, largely due to the conversion of stockholder loans and accrued payroll into equity.
- Capital Structure: The company issued significant common stock during the period to raise capital and settle debts, increasing shares outstanding from 31,030,382 to 38,485,094.
Outlook, Risks, and Management Commentary
- Going Concern Risk: Management explicitly states that the company's continuation is dependent on generating sufficient cash flow and obtaining additional financing. No assurance is given that FDA approval will be granted or that funding will be secured.
- Financing Needs: Significant additional financing is required to complete pre-clinical testing and proceed to Phase I, II, and III human testing. Management is pursuing strategic alliances and joint ventures.
- Operational Focus: Development activities have shifted primarily to patenting activities due to cost-cutting measures.
- Commitments: The company has employment agreements with future commitments of $411,000 in 1997 and $272,000 in 1998. There are also royalty obligations under license agreements ranging from $30,000 to $200,000 annually.
- Legal: No material litigation is currently pending.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $7,560 cash balance against the $411,000 in committed employment costs and ongoing operational expenses.
- Capital Raising: Confirm the status of the equity finance agreement (6% commission for raising $5M) and any new private placements or joint ventures mentioned in the outlook.
- Debt Conversion: Review the terms of the stock issued to retire stockholder loans ($229,980) and pay salaries ($343,853) to understand the dilution impact.
- Regulatory Path: Assess the timeline and probability of FDA approval for the pre-clinical products, as this is the primary blocker to revenue generation.
- Accrued Liabilities: Investigate the nature of the remaining $390,093 in accrued expenses and $158,960 in accrued payroll to determine immediate payment obligations.